A Study of the Cardiac Effects of Danicopan in Healthy Adults
Status:
Completed
Trial end date:
2018-10-12
Target enrollment:
Participant gender:
Summary
This was a randomized, double-blind, double-dummy, placebo- and positive-controlled, 2-arm
(Treatment Arm and Control Arm), parallel study to evaluate the effect of ACH-0144471
(danicopan) on the QT interval in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborator:
Achillion, a wholly owned subsidiary of Alexion
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination